Colossal Biosciences Shifts Scientific Strategy for De-Extinction - News Directory 3

The company's April 2026 announcement about the African bluebuck -- a recently extinct antelope -- demonstrates its ongoing commitment to de-extinction, but it also signals a shift toward applied conservation technologies.

Based on verified reporting from May 2026, including the discovery headline from Zamin.uz and primary sources from Colossal Biosciences, the biotechnology company has not announced a full abandonment of its de-extinction ambitions as of May 4, 2026. However, the company has shifted its strategic focus toward genetic rescue, conservation, and applied biotechnology -- prioritizing projects that directly benefit living species and ecosystems.

Here is the verified status of Colossal Biosciences as of May 2026:

Dallas-based Colossal Biosciences, known for its high-profile de-extinction projects like the woolly mammoth and dire wolf, has expanded its mission beyond resurrection to include broader conservation and genetic rescue initiatives. While the company continues to pursue de-extinction, its recent announcements emphasize scalable conservation platforms -- such as the $100 million Colossal Foundation, which funds projects like toxin-resistant quolls, amphibian genetic rescue, and AI-driven wildlife monitoring.

The company's April 2026 announcement about the African bluebuck -- a recently extinct antelope -- demonstrates its ongoing commitment to de-extinction, but it also signals a shift toward applied conservation technologies. According to Colossal's official statements, the bluebuck project is part of a broader effort to develop reproductive breakthroughs for endangered species and create BioVaults to preserve genetic diversity for thousands of species.

Colossal's strategic pivot is reflected in its recent funding and partnerships. In May 2026, the company secured $200 million in Series C funding, bringing its valuation to $10.2 billion. This funding will support not only de-extinction projects but also genetic rescue programs -- such as creating toxin-resistant quolls (a type of Australian carnivorous marsupial) and developing vaccines for endangered species.

Ben Lamm, Co-Founder and CEO of Colossal Biosciences, has stated in recent interviews that the company's mission is evolving to address both extinction and biodiversity loss through technology. While de-extinction remains a long-term goal, the immediate focus is on saving species at risk of extinction and leveraging genetic tools to restore ecosystems.

While Colossal has not abandoned de-extinction entirely, its recent announcements suggest a strategic emphasis on immediate conservation impact. The company's shift aligns with broader debates in the scientific community about whether de-extinction efforts should prioritize resurrecting lost species or saving those on the brink of extinction.

Critics argue that de-extinction projects divert resources from saving endangered species, while supporters believe such efforts can inspire conservation and provide tools for genetic rescue. Colossal's new approach attempts to address both perspectives by integrating de-extinction research with real-world conservation applications.

For now, Colossal remains committed to its flagship projects, including the woolly mammoth and dire wolf, but its expanded focus on genetic rescue and applied conservation suggests a more balanced strategy moving forward.

As of May 4, 2026, there is no official statement from Colossal indicating a complete abandonment of de-extinction. Instead, the company is broadening its mission to include both resurrection and rescue -- reflecting a growing recognition that saving species today is just as critical as reviving those lost to history.